Current status and advances in immunotherapy for advanced renal cell carcinoma

VernacularTitle:晚期肾细胞癌的免疫治疗现状与进展
Author: Ruyan CHEN ¹ ; Zhenming FU
Author Information

1. 武汉大学人民医院肿瘤中心，武汉　430060
Keywords: Carcinoma, renal cell; Immunotherapy; Immune checkpoint inhibitor
From: Journal of International Oncology 2025;52(2):124-128
CountryChina
Language:Chinese
Abstract: Approximately 25% of renal cell carcinoma (RCC) patients are already at an advanced stage at the time of initial diagnosis. Additionally, nearly 30% of patients with localized RCC eventually develop distant metastases even after undergoing radical surgery. Traditional chemotherapy and radiotherapy have shown limited effect on advanced RCC treatment, resulting in poor prognosis, with a 5-year survival rate of only about 8%. In recent years, immunotherapy for RCC has become a significant focus of research. With further research, the treatment options for advanced RCC have become increasingly diverse. The exploration of the current clinical applications and research advancements in immunotherapy for advanced RCC could offer medical evidence for optimizing treatment strategies for advanced RCC patients.